We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-12.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$4.02B
AUM Growth
+$78.1M
Cap. Flow
+$805M
Cap. Flow %
20.04%
Top 10 Hldgs %
52.6%
Holding
62
New
8
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
MXCT icon
MaxCyte
MXCT
+$211M
2
ABSI icon
Absci
ABSI
+$150M
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$140M
4
PACB icon
Pacific Biosciences
PACB
+$88.6M
5
DNA icon
Ginkgo Bioworks
DNA
+$87.7M

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$49.1M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$45.3M
3
NEO icon
NeoGenomics
NEO
+$22.1M
4
FULC icon
Fulcrum Therapeutics
FULC
+$12.1M
5
CLOV icon
Clover Health Investments
CLOV
+$9.68M

Sector Composition

Rank Sector Weight
1 Healthcare 91.14%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
BeOne Medicines Ltd
ONC
$32.6B
$54.5M 1.36%
150,000
– –
ALLO icon
27
Allogene Therapeutics
ALLO
$635M
$54M 1.34%
2,100,000
+875,000
+71% +$20.8M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$49M 1.22%
1,925,000
+615,000
+47% +$18.1M
ADPT icon
29
Adaptive Biotechnologies
ADPT
$3.68B
$48.9M 1.22%
1,440,000
– –
WGS icon
30
GeneDx Holdings
WGS
$2.01B
$38M 0.94%
+151,515
New +$52M
ALEC icon
31
Alector
ALEC
$168M
$37.7M 0.94%
1,650,000
– –
GBIO
32
DELISTED
Generation Bio
GBIO
$33.2M 0.83%
132,428
-28,693
-18% -$6.87M
OMIC
33
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$30.1M 0.75%
89,762
– –
FDMT icon
34
4D Molecular Therapeutics
FDMT
$527M
$30.1M 0.75%
1,115,455
-100
-0% -$2.85K
CRSP icon
35
CRISPR Therapeutics
CRSP
$4.88B
$29.8M 0.74%
266,430
– –
DNTH icon
36
Dianthus Therapeutics
DNTH
$5.8B
$28.4M 0.71%
243,849
+34,722
+17% +$4.05M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.7B
$22.9M 0.57%
1,200,000
– –
GLUE icon
38
Monte Rosa Therapeutics
GLUE
$1.3B
$21.4M 0.53%
960,883
– –
ZLAB icon
39
Zai Lab
ZLAB
$2.05B
$20M 0.5%
190,000
– –
ME
40
DELISTED
23andMe Holding Co
ME
$16.7M 0.42%
92,073
-45,000
-33% -$8M
MASS icon
41
908 Devices
MASS
$345M
$13.2M 0.33%
406,502
– –
RXRX icon
42
Recursion Pharmaceuticals
RXRX
$1.69B
$12.6M 0.31%
548,156
– –
ORIC icon
43
Oric Pharmaceuticals
ORIC
$1.1B
$12.6M 0.31%
601,515
– –
KRON
44
DELISTED
Kronos Bio
KRON
$12.2M 0.3%
583,436
– –
VRTX icon
45
CALL
Vertex Pharmaceuticals
VRTX
$119B
$9.07M 0.23%
+50,000
New +$9.76M
DBTX
46
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$9.02M 0.22%
1,170,048
-1,373
-0.1% -$10.5K
TKNO icon
47
Alpha Teknova
TKNO
$284M
$7.47M 0.19%
300,000
– –
ORTX
48
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.92M 0.15%
257,500
-64,043
-20% -$1.91M
SEER icon
49
Seer Inc
SEER
$123M
$5.18M 0.13%
150,000
– –
CELL
50
DELISTED
PhenomeX Inc. Common Stock
CELL
$3.91M 0.1%
200,000
– –
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Casdin Capital held 62 positions worth $4.02B, up 2% from $3.94B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $805M of net new capital in Q3 2021, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was MaxCyte: 13,971,334 shares worth $171M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was 23andMe Holding Co, an estimated $8M trimmed.

  • Casdin Capital's largest Q3 2021 buy was MaxCyte: 13,971,334 shares worth $171M.
  • Casdin Capital added most to Pacific Biosciences in Q3 2021, an estimated $88.6M increase.
  • Casdin Capital's biggest Q3 2021 reduction was 23andMe Holding Co, cutting an estimated $8M.
  • Casdin Capital fully exited Amyris Inc. in Q3 2021, selling an estimated $49.1M.
  • Casdin Capital's ten largest holdings make up 53% of its $4.02B portfolio in Q3 2021.
  • Casdin Capital opened 8 new positions and closed 8 in Q3 2021.
  • Casdin Capital's portfolio value rose 2% quarter-over-quarter to $4.02B.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.